Emergent BioSolutions Inc (Emergent) provides specialized products to commercial customers and the government to address medical needs and public health threats (PHTs). The company operates through a single reportable segment and recognizes revenue through three categories, namely, Product Sales, Contract Development and Manufacturing (CDMO) services, and Contracts and Grants.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities are focused on expanding and advancing its pipeline products, and device product candidates. Emergent’s platform technologies include Emergard, an auto-injector platform; Hyperimmune, a specialty plasma product manufacturing platform; and antiviral iminosugars platform. The company’s vaccine pipeline product candidates include AV7909, an anthrax vaccine product candidate in Phase III clinical trials intended for the treatment of bacillus anthracis; and CHIKV VLP in Phase III for the prevention of chikungunya virus. Its device pipeline products include AP003 (naloxone multidose nasal spray) in formative studies intended for the treatment of acute opioid overdose in Pre-Clinical; SIAN, a single-use intranasal spray device intended for use in patients with cyanide in Phase-I; and EGRD-001 Diazepam Auto-Injector for use as a nerve agent countermeasure in pre-clinical phase. Emergent’s Therapeutic pipeline includes UniFlu and WEVEE VLP in Phase I clinical trials for the treatment of Universal influenza vaccine and equine encephalitic VLP vaccine respectively. EBS-Lassa in Phase II trials for the treatment of Lassa fever; EBS-Marburg and EBS-Sudan in Pre-Clinical trials for tratment of Marburg virus disease and Sudan virus disease respectively. In FY2022, the company spent US$193.0 million on its R&D activities, which as a percentage of revenue stood at 17.2%.